Brave Asset Management Inc. Increases Holdings in Pfizer Inc. $PFE

Brave Asset Management Inc. boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 17.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,488 shares of the biopharmaceutical company’s stock after purchasing an additional 2,046 shares during the quarter. Brave Asset Management Inc.’s holdings in Pfizer were worth $327,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently made changes to their positions in PFE. GKV Capital Management Co. Inc. bought a new position in Pfizer in the first quarter worth approximately $27,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer in the 1st quarter valued at $28,000. North Capital Inc. bought a new position in shares of Pfizer in the 1st quarter worth $28,000. WPG Advisers LLC bought a new position in shares of Pfizer in the 1st quarter worth $35,000. Finally, Horizon Financial Services LLC purchased a new stake in shares of Pfizer during the 1st quarter worth $35,000. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

PFE has been the topic of several analyst reports. Bank of America lifted their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, September 20th. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Morgan Stanley lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Finally, Berenberg Bank decreased their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a report on Thursday, May 29th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $28.12.

Pfizer Stock Performance

Shares of PFE stock opened at $23.61 on Friday. The business has a fifty day moving average of $24.57 and a 200 day moving average of $24.16. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a market capitalization of $134.25 billion, a price-to-earnings ratio of 12.56, a price-to-earnings-growth ratio of 0.78 and a beta of 0.55.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the company earned $0.60 earnings per share. The company’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.